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plasma cells and elevation of IgG4 level in serum, which may affect virtually every organ and tissue in the organism. IgG4-related
ophthalmic disease may present as dacryoadenitis, myositis, other orbital tissues, hypophysitis or pachymeningitis causing cranial
neuropathies. The diagnosis of IgG4-related disease is based on a typical clinical scenario, supportive laboratory data, expected
radiological characteristics and distinct histopathological and immunohistochemical features. Corticosteroid followed by the use of
long-term immunosuppressive therapy is the most commonly attempted treatment.
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The term inflammatory pseudotumor has been used to
describe a heterogeneous group of mass-forming lesions in
various anatomic regions and organs characterized by prolif-
eration of fibroblasts and inflammatory infiltrate composed
mainly of lymphocytes and plasma cells. The condition has
been recognized since the 1800s under various names
depending of the organ affected, such as Mikulicz disease,
Riedel thyroiditis, lymphoplasmacytic sclerosing pancreatitis
or idiopathic hypertrophic pachymeningitis among many oth-
ers. During the first decade of this century, the discovery of
common features among these seemingly disparate condi-
tions was identified allowing the emergence of the fibro-
inflammatory condition now known as IgG4-related disease.
The international symposium on IgG4-related disease held
in Boston, Massachusetts in October 2011 with representa-
tion of various specialties and countries in its committee, rec-
ommended the unifying term of IgG4-related disease
followed by the organ or area affected as the preferred
nomenclature of this condition (i.e., IgG4-related dacryoade-
nitis or myositis or pachymeningitis).1The typical characteristics of IgG4-related disease include
tendency to form tumors, inflammatory infiltrate with IgG4
rich plasma cells and elevation of IgG4 level in serum.
Patients usually present with symptoms related to mass effect
or focal deficits caused by the compression of blood vessels
or nerves. Of interest in ophthalmology, IgG4-related disease
may affect any tissue but often presents as dacryoadenitis,
myositis, orbital inflammation, hypophysitis or pachymeningi-
tis causing cranial neuropathies.1 The differential diagnosis is
broad including inflammatory diseases and vasculitis such as
sarcoidosis, granulomatosis with polyangiitis, giant cell arter-
itis, Behcet’s disease, thyroid eye disease, inflammatory his-
tiocytosis or rheumatoid arthritis; neoplastic diseases such
as lymphoma, inflammatory myofibroblastic tumor, neoplas-
tic histiocytosis, meningioma or metastasis; and infectious
processes such as tuberculosis. Further, there is likely a group
of inflammatory conditions grouped in the inflammatory
pseudotumor category, which is still today considered idio-
pathic. Although IgG4-related disease is thought to comprise
a large number of cases previously labeled as idiopathic
inflammatory pseudotumor, its exact incidence is unknown.
Wallace et al. retrospectively examined 14 cases of pachy-e:
al.com
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that IgG4-related disease accounted for 4 of those cases or
66% of previously labeled as idiopathic cases.2 The other
10 cases were comprised of granulomatosis with polyangiitis
(3), rheumatoid arthritis (1), giant cell arteritis (1), neurosar-
coidosis (1), MALT lymphoma (1), lymphoma (1) and of undif-
ferentiated etiology (2). Furthermore, these findings raise the
question if biopsy specimens of cases previously labeled as
idiopathic inflammatory pseudotumor, should be reexamined
for IgG4-related disease when the original pathological sam-
ple is still available or to repeat a biopsy when the current
clinical course warrant and previous tissue sample are not suf-
ficient or unavailable.Pathophysiology
The pathophysiology of IgG4-related disease is poorly
understood. IgG4-related disease seems to sit at an intersec-
tion between different inflammatory markers.3 Many patients
have substantial allergic or atopic histories suggesting a
modified Th2 response is critical to this condition. IgG4-
related disease is most likely driven by an underlying autoim-
mune mechanism. There is higher risk for IgG4-related dis-
ease in certain genotypes and there is immune complex
deposition and increase in regulatory CD25 T cells. No pre-
cise triggers have yet been identified for the initiation of
IgG4-related disease. However, molecular mimicry by caus-
ing autoimmune reaction to a foreign antigen may be impor-
tant. Escherichia coli and Helicobacter pylori have been
implicated as possible candidates and source of molecular
mimicry in IgG4-related pancreatitis. Mast cells have been
shown to produce T helper 2 and regulatory T-cell cytokines
in tissues affected by this condition suggesting a role in dis-
ease pathogenesis.4 There are four subclasses of IgG, of
which IgG4 is the least common (<6%). IgG1-3 can activate
all complement, whereas IgG4 cannot. IgG 1,3 and 4 are
effective at opsonization of bacteria. Although IgG4 is
increased in tissues and serum in IgG4-related disease, it is
unclear if and how it would play a role in the pathophysiology
of this condition or if it is a mere epiphenomenon.Diagnosis
The diagnosis of IgG4-related disease is based on a typical
clinical scenario, supportive laboratory data, expected radio-
logical characteristics and distinct histopathological and
immunohistochemical features. As mentioned previously,
IgG4-related ophthalmic disease may involve the orbit
including lacrimal glands, extraocular muscles or other orbital
structures; affect the meninges causing ocular motor cranial
nerve palsies or optic neuropathy; and/or extend to adjacent
structures such as air sinuses or trigeminal nerve causing
additional symptoms (case report).
The serum levels of total IgG and IgG4 are usually ele-
vated in patients with IgG4-related disease and should be
checked when the disease is suspected. However, it is
increasingly clear that serum concentrations of IgG4 are unre-
liable as diagnostic marker in this condition. Approximately
20–40% of patients with biopsy-proven IgG4-related disease
have normal IgG4 concentrations at the time of diagnosis,
even before the institution of therapy.5 In addition, a propor-
tion of both healthy and disease controls has elevated serumIgG4 levels, although it is uncommon for levels in controls to
be more than twice the upper limit of normal.1 Furthermore,
the serum concentration of IgG4 does not correlate with dis-
ease activity or response to treatment. Recently, Carruthers
et al. estimated that elevation of serum IgG4 concentration
had a sensitivity of 90% and specificity of 60% with high neg-
ative predictive value of 96% but low positive predictive
value of 34% in the diagnosis of IgG4-related disease.6 Cere-
brospinal fluid (CSF) analysis in patients with IgG4-related
disease of the central nervous system may reveal mild to
moderate lymphocytic pleocytosis, a non-specific finding.
Therefore, the main value of CSF testing in those cases is
the exclusion of infection and cancer. Further, it is unclear
how sensitive or specific IgG4 measurement in CSF really is.2
Katsura et al. reviewed the radiological features in the
head, neck and brain of 17 histopathological confirmed cases
of IgG4-related disease, including CT and MRI techniques.7
The general radiological features found included well-
defined soft tissues masses showing homogeneous attenua-
tion/signal intensity, which enhanced homogeneously.
Lesions were iso- to hypointense relative to gray matter on
T2-weighted imaging. Bones adjacent to the lesions showed
remodeling with erosion or sclerosis, but without destruction.
Diffuse thickening of the dura mater was also seen. Lacrimal,
salivary and pituitary glands were preferentially affected. Per-
ineural spread of cranial nerves, notably the trigeminal nerve,
is characteristic, although not pathognomonic. Hardy et al.
found enlargement of the infraorbital nerve and canal in
patients with both, IgG4-related disease and benign reactive
lymphoid hyperplasia, with orbital involvement.8
The histopathology of IgG4-related disease was a specific
focus of the international symposium held in Boston, Massa-
chusetts in October 2011 mentioned previously. The authors
of those consensus guidelines recognized that although the
combination of histopathological features and immunohisto-
chemical stain results can provide strong supportive evidence
for the diagnosis of IgG4-related disease, careful correlation
with the clinical scenario and imaging characteristics of a par-
ticular patient is often required to arrive at a definitive diag-
nosis.9 However, while understanding the limitations of
pathological studies for the diagnosis of IgG4-related dis-
ease, diagnostic biopsy should be pursued as much as possi-
ble when encountering patients with this condition. The
consensus group concluded that the diagnosis of IgG4-
related disease requires both, an appropriate histological
appearance and increased numbers of IgG4 plasma cells in
tissue. The three major histopathological features associated
with IgG4-related disease are: (1) dense lymphoplasmacytic
infiltrate (with predominance of T lymphocytes); (2) fibrosis,
arranged at least focally in a storiform pattern (spiral or
whorled appearance); and (3) obliterative phlebitis. In most
instances, two of the three major histological features are
required for diagnosis. Other characteristic histopathological
features are phlebitis without obliteration of the lumen and
increased numbers of eosinophils. In addition, IgG4 immuno-
staining is strongly recommended because it is a simple and
highly reproducible test that provides strong confirmatory
evidence for the diagnosis. An IgG4/IgG plasma cell ratio
of >40% is considered a powerful tool supporting the diag-
nosis of IgG4-related disease. However, elevated levels of tis-
sue IgG4 may also be seen in other conditions such as
lymphoma, Rosai-Dorfman disease and rheumatoid arthritis.
Figure 1. Findings on MRI of orbits on presentation (top row) and 6 months later, after having received steroid treatment (bottom row), on coronal fat
saturated T2-weighted (A, C) and gadolinium-enhanced T1-weighted images (B, D), showing enlargement of the right lateral rectus muscle with
homogenous attenuation and enhancement with improvement at 6 months. Mucosal thickening of adjacent air sinuses is also appreciated.
Figure 2. Histologic features of left medial rectus muscle biopsy. Hematoxylin and eosin stain at low (10x magnification) (left) and high power (40
magnification) (middle) demonstrates a perivascular mixed inflammatory infiltrate and venulitis without obliteration. IgG4 immunohistochemical stain
(right) demonstrates plasma cells with strong IgG4 expression.
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IgG4-related disease may affect one organ or tissue,
spread to contiguous areas, or be multifocal and even sys-
temic. The clinical course of the disease is variable, although
usually slowly progressive and chronic; it may experience
spontaneous remission at least temporarily, or have com-plete response to treatment.10 Although the standard first
line therapy consists of steroids, there is no uniform recom-
mendation.11 Indeed, an early and robust positive response
to oral or parenteral steroids is characteristic in this condi-
tion, much so that the lack of response to steroids questions
the diagnosis. However, their effect may not last, requiring
the addition of other treatments. Further, the use of other
56 L.J. Mejicoimmunosuppressant medications is recommended to prevent
adverse effects of chronic use of steroids. Mycophenolate
mofetil (MMF) is an immunosuppressive agent with favorable
toxicity profile reported to work in IgG4 and other inflamma-
tory eye diseases.10,12 Rituximab has also been demonstrated
to be an effective alternative allowing for discontinuation of
steroids.13 Other immunosuppressant agents used include
methotrexate, azathioprine and cyclophosphamide. The role
of radiotherapy is uncertain, although may play a role in local-
ized disease such as unilateral orbital involvement. Surgical
resection is of limited value and not recommended.
Conclusions
IgG4-related disease is a fibro-inflammatory condition
recently recognized as a common form of inflammatory pseu-
dotumor disorders in virtually every organ or tissue in the
body. It is likely of autoimmune mechanism and has a variable
but usually progressive clinical course. It has a tendency to
form tumors with lymphocytic inflammatory infiltrate rich in
IgG4 plasma cells with fibrosis and elevation of IgG4 in
serum. The diagnosis is based on clinical presentation with
characteristic appearance on MRI, elevated serum IgG4 level
and distinctive features on histopathological and immunohis-
tochemical studies. Most accepted treatment nowadays con-
sists of steroids initially with an expected robust response,
followed by the use of long-term immunosuppressive ther-
apy. IgG4-related disease should always be considered by
the clinician suspecting an inflammatory condition, because
although it may be an uncommon disease, it is likely under
diagnosed.
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Appendix A. Case report
A 43-year-old man was referred to neuro-ophthalmology
with diplopia for 15 months. He had initially presented to
his ophthalmologist with diplopia and palpebral edema in
the right eye 15 months prior. MRI of the orbits then revealed
enlargement of the right lateral rectus muscle with homoge-
nous attenuation and enhancement, as well as mucosal thick-
ening of adjacent air sinuses (Fig. 1, top row). He received
oral prednisone for 2 weeks with complete resolution of
symptoms. However, he developed recurrence of symptoms
2 months later, which resolved again after a second round of
oral prednisone. A month later his symptoms returned and he
was seen by an orbit specialist, who instituted a longer course
of oral steroids. Blood serology for various inflammatory and
connective tissue diseases was non-contributory. Repeat MRI
6 months after initial presentation revealed improvement of
right lateral rectus enlargement (Fig 2. bottom row). Symp-
toms resolved once again but recurred a few weeks after
stopping treatment. A biopsy of the right lateral rectus mus-
cle showed chronic inflammation. He then underwent frac-tionated radiation therapy with a dose of 2000 centigray
(cGy) to the right orbit only. His diplopia improved but was
still present on right gaze. Four months after completing
radiation therapy, he developed worsening diplopia and
was found to have new limited adduction of the left eye.
An MRI of the orbits confirmed enlargement of the left med-
ial rectus (not shown).
Neuro-ophthalmic consultation was completed 15 months
after initial presentation. Serum IgG4 level was elevated at
156 mg/dL (4.0–86.0 mg/dL). The first biopsy sample was
obtained, but the tissue was deemed not sufficient for repeat
testing. Therefore, a second biopsy, this time of the left med-
ial rectus was performed. Microscopic examination of the
biopsy showed perivascular mixed inflammatory infiltrate
and venulitis without obliteration. Further, IgG4 immunohis-
tochemical stain demonstrated plasma cells with strong
IgG4 expression (Fig. 2). A diagnosis of IgG 4-related orbital
myositis was made. He then initiated treatment with oral
prednisone and mycophenolate mofetil 1,000 mg twice a
day. The dose of oral prednisone was gradually decreased
and stopped 3 months later. At the 10-month follow-up visit,
he still had mild diplopia on certain position of gaze and no
new symptoms. Furthermore, the degree of strabismus had
improved in a remarkable way.
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